Aclarion signed a second commercial agreement with New York City-based Weill Cornell Medicine, according to a May 5 news release.
The new agreement brings Aclarion’s Nociscan spine diagnostic tool to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by Roger Härtl, MD.
Dr. Härtl is studying the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate injections.
“Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate,” Ryan Bond, Acarion chief strategy officer, said in the release. “Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
